The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population

Clinical Biochemistry

Volumn 43, Issue 18, 2010, Pages 1399-1404

  Chiang, Chia Hung ^a,b   Huang, Chin Chou ^a,b   Chan, Wan Leong ^a   Chen, Jaw Wen ^a,b   Leu, Hsin Bang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

C reactive protein; Cardiovascular diseases; Fatty liver

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK; RISK FACTOR; SENSITIVITY ANALYSIS;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FATTY LIVER; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 78149498510     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.09.003     Document Type: Article

References (41)

1. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005, 22:1129-1133.
2. Lonardo A., Bellini M., Tartoni P., Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997, 29:351-356.
3. Araujo L.M., De Oliveira D.A., Nunes D.S. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diab Metab 1998, 24:458-462.
4. el-Hassan A.Y., Ibrahim E.M., al-Mulhim F.A., Nabhan A.A., Chammas M.Y. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992, 65:774-778.
5. Fan J.G., Zhu J., Li X.J., Chen L., Li L., Dai F., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005, 43:508-514.
6. Nomura H., Kashiwagi S., Hayashi J., Kajiyama W., Ikematsu H., Noguchi A., et al. Prevalence of gallstone disease in a general population of Okinawa, Japan. Am J Epidemiol 1988, 128:598-605.
7. Patel A.A., Torres D.M., Harrison S.A. Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol 2009, 43:970-974.
8. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48:634-642.
9. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L., et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004, 53:1020-1023.
10. Tarantino G., Saldalamacchia G., Conca P., Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007, 22:293-303.
11. Kogiso T., Moriyoshi Y., Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatol Res 2007, 37:711-721.
12. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143:722-728.
13. Sung K.C., Ryan M.C., Wilson A.M. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009, 203:581-586.
14. Akahoshi M., Amasaki Y., Soda M., Tominaga T., Ichimaru S., Nakashima E., et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001, 24:337-343.
15. Targher G., Bertolini L., Poli F., Rodella S., Scala L., Tessari R., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541-3546.
16. Day C.P., James O.F. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 1998, 27:1463-1466.
17. Loria P., Lonardo A., Targher G. Is liver fat detrimental to vessels? Intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008, 115:1-12.
18. McKimmie R.L., Daniel K.R., Carr J.J., Bowden D.W., Freedman B.I., Register T.C., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103:3029-3035.
19. Petit J.M., Guiu B., Terriat B., Loffroy R., Robin I., Petit V., et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009, 94:4103-4106.
20. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H., Shin J.Y. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diab Care 2009, 32:147-152.
21. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004, 109:433-438.
22. Anderson K.M., Odell P.M., Wilson P.W., Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 1991, 121:293-298.
23. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
24. Soderberg C., Stal P., Askling J., Glaumann H., Lindberg G., Marmur J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
25. Wang Y., Dong J., Liu H.Y., Wang D.Q., Tian Y.P. Biochemical characteristics and risk factors in non-alcoholic fatty liver. Front Biosci (Elite Ed) 2010, 2:105-110.
26. Hamaguchi M., Kojima T., Takeda N., Nagata C., Takeda J., Sarui H., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007, 13:1579-1584.
27. Cali A.M., Zern T.L., Taksali S.E., de Oliveira A.M., Dufour S., Otvos J.D., et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diab Care 2007, 30:3093-3098.
28. Wieckowska A., Papouchado B.G., Li Z., Lopez R., Zein N.N., Feldstein A.E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008, 103:1372-1379.
29. Biddinger S.B., Hernandez-Ono A., Rask-Madsen C., Haas J.T., Aleman J.O., Suzuki R., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008, 7:125-134.
30. Guillen N., Acin S., Navarro M.A., Perona J.S., Arbones-Mainar J.M., Arnal C., et al. Squalene in a sex-dependent manner modulates atherosclerotic lesion which correlates with hepatic fat content in apoE-knockout male mice. Atherosclerosis 2008, 197:72-83.
31. Volzke H., Robinson D.M., Kleine V., Deutscher R., Hoffmann W., Ludemann J., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005, 11:1848-1853.
32. Targher G., Bertolini L., Padovani R., Rodella S., Zoppini G., Zenari L., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diab Care 2006, 29:1325-1330.
33. Assy N., Djibre A., Farah R., Grosovski M., Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010, 254:393-400.
34. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
35. Park S.H., Kim B.I., Yun J.W., Kim J.W., Park D.I., Cho Y.K., et al. Insulin resistance and c-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004, 19:694-698.
36. Frith J., Day C.P., Henderson E., Burt A.D., Newton J.L. Non-alcoholic fatty liver disease in older people. Gerontology 2009, 55:607-613.
37. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
38. Yeh E.T., Willerson J.T. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003, 107:370-371.
39. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
40. Meshkani R., Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009, 42:1331-1346.
41. Yoneda M., Mawatari H., Fujita K., Iida H., Yonemitsu K., Kato S., et al. High sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007, 42:573-582.